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Abstract
Positron emission tomography (PET) is a powerful in vivo imaging technique capable of 
providing dynamic information on biochemical processes in the living human subject. 
Applications of PET in oncology, neurology, psychiatry, cardiology and other medical 
specialties continue to grow. The use of PET relies on the characteristics and availabil-
ity of appropriately labeled radiopharmaceuticals. Carbon-11 is one of the most useful 
radionuclides for PET chemistry, since its introduction into a biologically active mol-
ecule dose not modify the biochemical properties of the compound. [11C]Carbon dioxide 
(11CO
2
), produced by cyclotron, is the most common and versatile primary labeling pre-
cursor in the production of 11C–labeled radiopharmaceuticals.
Keywords: positron emission tomography, Carbon-11, radiopharmaceutical, molecular 
imaging, cyclotron
1. Introduction
Carbon-11 (11С) is an artificial radioisotope of carbon. Crane and Lauristen made the production 
of this short-lived radionuclide and investigated its physical properties in 1934 [1]. They dem-
onstrated that carbon-11 decays by positron emission to the stable nuclide 11B [Eq. (1)]. Due to 
its favorable decay characteristics (t
1/2
 = 20.33 min, 98.1% by β+ emission, 0.19% by electron cap-
ture), carbon-11 was considered as a useful labeling tool for medical purposes. The first biologi-
cal application of carbon-11 was published by Ruben in 1939 who investigated photosynthesis 
in plants using [11C]carbon dioxide [2]. The potential of 11C-labeled compounds for non-invasive 
probing of physiological and biochemical processes in humans was subsequently realized [3]. 
The first carbon-11 experiment on humans was performed by Tobias in 1945 who studied the 
fixation of [11C]carbon monoxide by red blood cells [4]. However, the use of carbon-11 was 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
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limited in next 20 years [5]. This delay was a consequence of easy access to reactor-produced 
carbon-14 from the 1950s, which superseded the use of cyclotron-produced carbon-11. Until 
late 1950s, the concepts of emission and transmission tomography were introduced by David 
Kuhl and Roy Edwards. The interest in carbon-11 was renewed and the application of carbon-11 
was extended in 1960s.
  
 11  C  → 11  B +  β +  +  v 
e
  + 0.96 MeV 98.1%
    
 11  C +  e −   → 11  B +  v 
e
  + 1.98 MeV 0.19% (1)
Decay of carbon-11 by positron emission or electron capture.
Positron emission tomography (PET) is a type of functional molecular imaging technique 
using probes, known as radiotracers, consisting of bioactive molecules tagged with positron-
emitting radionuclides [6]. As carbon-11 undergoes positron emission decay, it emits a posi-
tron. The positron travels a short distance in the surrounding tissue until it collides with 
an electron. The annihilation produces a pair of gamma rays, which are emitted simultane-
ously in nearly opposite directions with energy of 511 keV each. The photons can be detected 
by pairs of collinearly aligned detectors in coincidence. The detectors of a PET system are 
installed in a ring-like pattern, which allows measurement of radioactivity through the organ 
of interesting at large angles and radial distances. The three-dimensional images can be gen-
erated by reconstruction (Figure 1). The ability to image and monitor molecular events in vivo 
and in real time is of great value for unveiling a detailed picture of fundamental biochemical 
and physiological processes in living organisms [7]. Information about metabolism, receptor/
enzyme function, and biochemical mechanisms in living subjects can be obtained directly 
from PET imaging studies. The recent development of hybrid instrument combines func-
tional PET with an anatomical modality such as computerized tomography (CT) or magnetic 
Figure 1. The principle behind PET imaging: (a) the injection of radiopharmaceuticals; (b) positron travels a short 
distance and collides with an electron, then two 511 keV gamma rays emit simultaneously at approximately 180° to each 
other after annihilation; (c) system detects gamma rays and then generates three-dimensional images.
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 resonance imaging (MRI). The fusion offers more precise images with accurate functional 
assessment from PET and anatomical information form CT or MRI. Applications of PET in 
oncology [8–12], neurology [13–16], psychiatry [17–19], cardiology [20, 21] and other medical 
specialties [22–24] became one of the fastest growing area in radiology [25].
The use of PET relies on the availability of appropriately labeled radiopharmaceuticals. 
Carbon-11 is one of the most useful radionuclides for PET chemistry, since the carbon is pres-
ent in any organic molecule so that the introduction of carbon-11 in a molecule does not 
modify the properties of this molecule. In addition, the short half-life of carbon-11 allows for 
l consecutive in vivo studies with injections of various radiotracers in the same subject on the 
same day. The pioneering work in the area of radiochemistry at the Washington University 
in 1960s demonstrated the great potential of 11C-labeled compounds in biological sciences [5]. 
The simple cyclotron production of [11C]carbon dioxide (11CO
2
) made it possible to be exten-
sively used as a starting point for the synthesis of different kinds of 11C-labeled compounds 
[26–28]. With the increasing demand of radiotracers and continuous developments of organic 
chemistry, a number of methodologies have been developed in recent years to enhance pro-
duction of 11C-radiotracers both from a technical and chemical point of view. However, [11C]
carbon dioxide is still the most common and versatile primary labeling precursor in the pro-
duction of 11C-labeled radiopharmaceuticals. This chapter focus on the use of [11C]carbon 
dioxide as the starting point for radiolabeling PET radiopharmaceuticals (Scheme 1).
2. Carbon-11 chemistry
2.1. Cyclotron: generation of carbon-11
Several nuclear reactions can be used to produce carbon-11 [29, 30]. Among these processes the 
14N(p,α)11C nuclear reaction is by far the most convenient and most commonly used method 
Scheme 1. Representative transformations in [11C]carbon dioxide radiochemistry.
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Figure 2. Automatical synthesis equipment in lead-shielded fume hoods.
of producing carbon-11. The reaction is performed by high-energy proton bombardment of a 
cyclotron target containing nitrogen gas. Depending on the addition of gas (up to 2% of O
2
 or 
5–10% of H
2
) to the nitrogen gas in the target, carbon-11 can be obtained as [11C]CO
2
 or [11C]CH
4
 
(Scheme 2). [11C]Carbon dioxide is the most important and versatile primary labeling precur-
sor for 11C-labeling. Cyclotron-produced [11C]CO
2
 can be used directly for the 11C-labeling of 
organic molecules (Scheme 1).
2.2. Radiochemistry: general considerations
Carbon-11 is a radionuclide that emits high-energy radiation. Therefore, the traditional hands-
on manipulations used in synthetic chemistry are not feasible. In order to avoid unnecessary 
radiation exposure to the operators, the radiosynthesis of PET tracer needs to be undertaken 
by automated or remote-controlled synthesis equipment housed inside lead-shielded fume 
hoods (hot-cells) [6, 7]. This is also important from the perspective of good manufacturing 
practice (GMP) where a reproducible and operator-independent production is required to 
control the quality of the radiopharmaceuticals. Figure 2 shows the radiochemistry laboratory 
at University of Michigan and a typical carbon-11 radiosynthesis module.
The half-life of carbon-11 is sufficiently long for synthesis and purification. However, the radio-
chemical yield is a function of chemical yield and radioactive decay. Thus the radiosynthesis 
time should be kept as short as possible. Ideally, a 11C-radiopharmaceutical is synthesized, 
Scheme 2. Generation of primary labeling precursors from cyclotron.
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purified, formulated and analyzed within a timeframe of roughly 2–3 physical half-lives of 
the radionuclide, or 40–60 min for carbon-11. In addition, the strategies for the radiolabeling 
should aim to introduce carbon-11 in the synthetic sequence as late as possible [31–33].
The specific radioactivity (SA), a measure of the radioactivity per unit mass of the final radio-
labeled compound, is another important aspect of 11C-chemistry. Since only a trace amount of 
[11C]carbon dioxide is generated in the cyclotron, the theoretical maximum specific radioac-
tivity for 11C-radiolabeled compound is 3.4 × 105 GBq/μmol. However, it is practically impos-
sible to achieve this number, because of unavoidable isotopic dilution by naturally occurring 
Radiotracers Labeling methods Targets References
[11C]Acetate Grignard reaction Tricarboxylic acid cycle—Cardiac, 
Oncology
[35, 36]
[11C]Butanol Grignard reaction Blood flow [37]
[11C]CFNa Methylation Opioid [36, 38–40]
[11C]Choline Methylation Oncology [36, 41, 42]
[11C]DASBb Methylation Serotonin transporter [36, 43]
[11C]DTBZc Methylation Vesicular monoamine transporter 2 [36, 44]
[11C]FMZd Methylation GABA
A
 receptor [36]
[11C]HEDe Methylation Adrenergic [36]
[11C]Methionine Methylation Oncology [36]
[11C]OMARf Methylation Cannabinoid receptor 1 [45]
[11C]Palmitate Grignard reaction Cardiac [35]
[11C]PBR28g Methylation Neuro, cardiac and oncology [36, 46–48]
[11C]PiBh Methylation Amyloid [36]
[11C]PMPi Methylation Acetylcholinesterase [36, 49]
[11C]Raclopride Methylation Dopamine [36, 40, 43, 50]
[11C]Sarcosine Strecker reaction Prostate cancer [51]
[11C]WAY100635j Grignard reaction 5HT
1A
 receptor [52, 53]
a[11C]Carfentanil.
b3-Amino-4-(2-[11C]dimethylaminomethylphenylsulfanyl)-benzonitrile.
c[11C]Dihydrotetrabenazine.
d[11C]Flumazenil.
e[11C]Meta-hydroxyephedrine.
fN-acetyl-N-(2-[11C]methoxybenzyl)-2-phenoxy-5-pyridinamine.
g1-(2,4-dichlorophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H–pyrazole-3-carboxamide.
h[11C] Pittsburgh Compound B.
i1-[11C]Methyl-piperidin-4-yl propionate.
jN-[2-[4-(2-[11C]methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide).
Table 1. 11C-radiotracers in University of Michigan PET center for clinical application.
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carbon-12 species during the processes. Typical specific activities of 11C-radiolabeled com-
pounds are in the order of 50–1000 GBq/μmol [34]. For imaging a patient, less than 1 GBq 
of radioactivity is normally enough. That means very low amounts of compound need to 
be administered for PET imaging, typically in picomolar to nanomolar scale. This prevents 
undesired pharmacological or toxic effects during the in vivo studies. Thus, a labeling path-
way should be designed to minimize contamination of carbon-12 species. Furthermore, due to 
tracer levels of carbon-11, the amount of the non-radioactive reagents is in large excess (about 
103–104 fold), which drives the reaction at pseudo first order kinetics. By consequence, small 
impurities in reagents or solvents may have a significant influence on the reaction outcomes. 
Therefore, the quality of regents used in radiosynthesis needs special attention.
Radiopharmaceuticals can range from the small and simple to the large and complex. A tracer 
should be designed in such a way that it can be probing a specific function within the organ of 
interest [3]. It is important that the physical half-life of the radionuclide matches the biological 
half-life of the studied process. For example, carbon-11 is not suitable for radiolabeled peptides 
or antibodies, which need a few hours of blood circulation to accumulate the activity in a tumor.
2.3. Application of carbon-11: examples of radiopharmaceuticals
Since its infancy in the early 1960s, PET has attracted increasing attention as a powerful tool 
for investigating the biochemical transformations of drugs and molecules in the living sys-
tem. With the development of PET imaging technology and novel synthetic methodology, 
11C-labeled radiopharmaceuticals have been extensively used for the highly sensitive non-
invasive measurement of biochemical physiological processes in living human subjects. As 
examples, Table 1 summarizes 11C-radiotracers available in University of Michigan PET cen-
ter for routine clinical application.
3. [11C]Carbon dioxide: starting point for labeling PET 
radiopharmaceuticals
The simple cyclotron production of [11C]carbon dioxide gave a starting point for the synthesis 
of important classes of compounds such as carboxylic acids [26], aldehydes [27], and alco-
hols [28]. However, due to low chemical reactivity of [11C]CO
2
, a broad spectrum of different 
11C-labeled synthetic intermediates have been prepared as useful secondary labeling precur-
sors (Scheme 1). With the increasing importance of PET in medical research and continu-
ous developments of novel organic chemical techniques, 11C-labeling methodology is rapidly 
growing. This chapter addresses selected commonly used methods and examples. For more 
detailed information see comprehensive reviews [7, 54, 55]
3.1. [11C]CO
2
 direct incorporation
[11C]Carbon dioxide is the most important and versatile primary labeling precursor for 
11C-radiolabeling, since it is produced directly from cyclotron. The electrophilic carbon in [11C]
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CO
2
 can be used as a carbonyl source and trapped by an appropriate nucleophilic component. 
For example, [11C]acetate as a PET radiopharmaceutical for both myocardial imaging and can-
cer detection was synthesized via methyl magnesium chloride with [11C]CO
2
 (Scheme 3) [56].
The [11C]carboxymagnesium halides also can be converted into more reactive [11C]carboxylic 
acid chloride to form amide with amines. The important 5HT
1A
 receptor ligand WAY100635 
was produced by this manner (Scheme 4) [52, 53].
More recently, [11C]CO
2
 fixation further expanded the synthetic possibility for 11C-labeling 
by direct incorporation of [11C]CO
2
. The first report on [11C]CO
2
 fixation was the synthesis of 
11C-labeled carbamates [57, 58]. The scope of this method was broadened to [11C]ureas and [11C]
oxazolidinones via the formation of an 11C-labeled isocyanate or carbamoyl anhydride inter-
mediate [54, 58–60]. For example, the reversible monoamine oxidase B (MAO-B) radioligand, 
[11C]SL25.1188, previously prepared using the technical demanding [11C]phosgene approach, 
was radiolabeled in high yield via [11C]CO
2
 fixation [61, 62]. This radioligand was recently 
translated for human PET imaging (Scheme 5) [54, 63].
3.2. [11C]Methylation
The introduction of [11C]methyl iodide as a second labeling precursor 30 years ago was one 
of the great milestones in PET radiochemistry [64, 65]. So far, the most common method in 
11C–labeling is heteroatom (N, O, S) methylation. Converting [11C]MeI to more reactive [11C]
methyltriflate ([11C]MeOTf) [64, 66] by passing [11C]MeI through a small column containing 
silver triflate around 200°C [67] significantly increases efficiencies of 11C–methylation. This 
innovation makes it possible to 11C-methylate heteroatoms in 3–5 min at room temperature. 
[11C]Methyl iodide can be prepared via two methods (Scheme 1). The so-called “wet” method 
developed in 1976 [64, 65] is based on reducing [11C]CO
2
 using LiAlH
4
 followed by reaction 
with hydroiodic acid. An alternative method, referred to as the “gas phase” method, was 
developed in the 1990s. This method exploits the reduction of [11C]CO
2
 by H
2
/Ni at 350°C 
and then conversion of [11C]methane into [11C]MeI by iodination with iodine vapor at high 
temperatures (700–750°C) in the gas phase [66, 68].
The incorporation of the [11C]methyl group into a target molecule is generally simply alkylation 
on N-, O-, and S-nucleophiles (e.g., HED, DTBZ, methionine). The tracer amount of [11C]MeII 
or [11C]MeOTf in the reaction leads to extraordinary stoichiometry. The stoichiometric relation 
can reach a factor of 104:1 resulting in pseudo-first order kinetics of heteroatom methylation 
reactions. Therefore, the conversion rate is highly increased and the reasonable radiochemical 
yields can be reached within short reaction times of 3–5 min. The problems with polyalkylation 
in normal stoichiometric methylation of amines.do not occur in the 11C-methylation processes.
Scheme 3. Synthesis of [11C]acetate.
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Figure 3. Representative 11C-radiotracers labeled by methylation.
The reaction can be performed using a traditional vial-based approach (e.g., CFN, FMZ) or using 
solid support either on-cartridge (e.g., choline) or flow-based loop methods (e.g., PIB, DASB, 
raclopride) (Figure 3) [39, 41, 43]. All these methods are very convenient from automation pro-
spective. The use of commercially available fully automated synthesis modules for production 
of clinical radiopharmaceutical doses enhances the speed, efficiency, reliability, and safety of 
radiosyntheses, as well as compliance with GMP regulations. For detail procedures see [38–43].
Scheme 4. Synthesis of [11C]WAY100635.
Scheme 5. Synthesis of [11C]SL25.1188.
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To further expand the number of 11C-labeled compounds, the development of novel 11C–C 
bond forming reactions continues to gain attention. For example, several palladium-mediated 
cross-coupling reactions have been shown to be effective 11C-labeling. The first application was 
reported in 1995 [69]. The feasibility of incorporating [11C]methyl groups into arenes, alkenes 
as well as alkanes was demonstrated by the reaction with the corresponding organostannanes 
and boranes in Stille and Suzuki cross-coupling reactions (Scheme 6) [70]. Due to the toxicity 
of the precursor and reagents used, the purification and quality control are more complicated 
comparing with those of simply methylation. Considering the short half-life of carbon-11, the 
application of this method for clinical dose production is currently underexploited. With the 
development of techniques and simplification of processes, this labeling strategy could be 
more widely adopted.
3.3. [11C]Cyanation
[11C]HCN is another important secondary labeling precursor (Scheme 1), because nitriles are 
not only frequently present in biologically active molecules but also represent a versatile func-
tional group that can be readily converted into 11C-labeled amides, carboxylic acids or amines 
(Scheme 7) [54, 71]. [11C]HCN is usually prepared by the reduction of [11C]CO
2
 to [11C]CH
4
, 
using H
2
 over nickel (400°C), and then converted into [11C]HCN by reaction with NH
3
 over 
platinum at elevated temperature (950°C) [72].
[11C]HCN can be used directly to form [11C]methyl-2-cyanoisonicotinate and [11C]1-succinonitrile 
by a Reissert-Kaufmann type reaction (Scheme 7a) and Michael addition (Scheme 7b), respec-
tively [73]. It may convert to [11C]CuCN and react with aryl halides through the Rosenmund-
von Braun reaction for the synthesis of [11C]LY2232645(Scheme 7d) [74–76]. 11C-labeled amino 
acids, for example, [11C]Sarcosine, can be prepared using [11C]HCN in the Strecker reaction 
(Scheme 7c) [51, 77, 78]. In recent years, palladium-catalyzed and copper-mediated cyanations 
have gained increasing attention [79–82]. Vasdev and co-workers employed arylboronic acids 
and [11C]CsCN to prepare aromatic 11C-nitriles (Scheme 7f), which was applicable to a broad 
range of substrates [80].
3.4. [11C]Carbonylation using [11C]CO
[11C]Carbon monoxide is an attractive secondary precursor for 11C-chemistry since the wide 
variety of carbonyl containing molecules can be synthesized through carbonylation reactions. 
[11C]CO is readily available by the reduction of [11C]CO
2
 over zinc or molybdenum [83, 84]. 
However, the application of [11C]CO was underexploited due to its poor reactivity and low 
solubility in organic solvents. Until recently, new methods have been developed to overcome 
Scheme 6. Synthesis of [11C]M-MTEB by Suzuki or Stille reactions.
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Scheme 8. Free-radical photoinitiated 11C-carbonylation reaction.
the shortcomings, from technical and chemical points of the view [85–88]. The first report was 
by Kihlberg and co-workers in 1999, where [11C]CO was allowed to react in a small autoclave 
under high pressure (>350 Bar) [89]. Low-pressure and ambient temperature techniques have 
been achieved lately [90–92]. The most widely applied 11C-carbonylation method used [11C]
CO is the palladium-mediated carbonylation reaction [93–96]. Rhodium-catalyzed carbon-
ylation reactions provide an alternative route for the introduction of [11C]CO into organic 
molecules [97–99]. Free-radical photoinitiated 11C–carbonylation reactions have been used to 
synthesize 11C-labeled aliphatic acid, esters and amides recently (Scheme 8) [100–104].
Scheme 7. Some transformations in [11C]HCN radiochemistry: (a) radiosynthesis of [11C]methyl-2-cyanoisonicotinate 
by a Reissert-Kaufmann type reaction; (b) direct formation of [11C]1-succinonitrile via Michael addition; (c) the Strecker 
reaction for the synthesis of [11C]Sarcosine; (d) and (e): [11C]CuCN can be reacted with aryl halides through the 
Rosenmund-von Braun reaction to afford [11C]LY2232645 and other aromatic [11C]nitriles; (f) copper-mediated synthesis 
of aromatic [11C] nitriles from arylboronic acids.
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4. Future perspectives
This review introduces the field of canbon-11 radiochemistry through a general overview, 
but is not meant to be comprehensive. As the field is fast growing, more traditional chemists 
join the radiochemistry arena worldwide. Carbon-11, one of the most important radioisotopes 
in nuclear medicine, is foreseen to have endless opportunities for further innovation. Due 
to the short half-life, efficiency and simplicity is always the key to 11C-labeling techniques. 
Recently developed transition-metal-mediated reactions have broadened the labeling scope 
and allowed 11C-labeling of a range of different bioactive molecules.
11C-chemistry is a hybrid science between organic chemistry and engineering. To meet the 
growing demand and increasing regulation of radiopharmaceuticals, the fully automated or 
kit-like synthetic devices have been developed and will be required to be used in the manu-
facture of clinical doses to improve the reliability and safety.
Furthermore, synthetic pathways with better economical output and environmental manage-
ment is another important aspect. The first example of a green radiochemistry laboratory at 
University of Michigan successfully prepared 11 radiopharmaceuticals for routine clinical 
application using ethanol as the only organic solvent [105]. The removal of all other organic 
solvents from the process simplifies production and quality control testing. The robust and 
reliable methods are increasingly applied in various PET facilities around the world.
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